Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Charles H. Sherwood sold 22,228 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $60.06, for a total value of $1,335,013.68. Following the transaction, the chief executive officer now owns 158,297 shares in the company, valued at approximately $9,507,317.82. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Anika Therapeutics Inc. (NASDAQ ANIK) traded down 0.63% during midday trading on Tuesday, hitting $59.53. The company had a trading volume of 55,482 shares. The company’s 50 day moving average is $57.72 and its 200 day moving average is $50.52. The stock has a market cap of $872.59 million, a price-to-earnings ratio of 26.45 and a beta of 1.66. Anika Therapeutics Inc. has a 12-month low of $41.38 and a 12-month high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.32. The firm had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The firm’s quarterly revenue was up 25.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.57 earnings per share. On average, equities analysts anticipate that Anika Therapeutics Inc. will post $2.20 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Anika Therapeutics Inc. (ANIK) CEO Sells $1,335,013.68 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/24/anika-therapeutics-inc-anik-ceo-sells-1335013-68-in-stock.html.

A number of institutional investors have recently bought and sold shares of ANIK. State of Alaska Department of Revenue boosted its stake in shares of Anika Therapeutics by 79.5% during the 2nd quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 1,272 shares during the period. Mason Street Advisors LLC lifted its stake in shares of Anika Therapeutics by 7.1% in the 1st quarter. Mason Street Advisors LLC now owns 3,423 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 228 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Anika Therapeutics by 68.4% in the 1st quarter. Victory Capital Management Inc. now owns 3,452 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,402 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in shares of Anika Therapeutics by 3.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 100 shares during the last quarter. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Anika Therapeutics in the 1st quarter valued at $204,000. 84.44% of the stock is owned by hedge funds and other institutional investors.

Several research firms have issued reports on ANIK. Zacks Investment Research upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. BidaskClub upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 8th.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.